

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
November 3, 2022**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

ASLAN Pharmaceuticals Limited

File No. 333-223920 - CF#35819

ASLAN Pharmaceuticals Limited submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information they excluded from the Exhibits to a Form F-1 registration statement filed on March 26, 2018, as amended.

Based on representations by ASLAN Pharmaceuticals Limited that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.5	through December 20, 2027
Exhibit 10.6	through December 20, 2027
Exhibit 10.7	through December 20, 2027

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Dana Hartz
Chief, Knowledge Management Office